Introduction: We evaluated differences in the clinicopathologic characteristics and prognosis based on the presence of ground glass opacity (GGO) components in small‐sized lung adenocarcinoma. Methods: We retrospectively investigated 634 lung adenocarcinomas classed as c‐stage IA in the eighth edition TNM classification. Staging was defined according to the solid component size measured by thin‐section computed tomography. All tumors were grouped into either a GGO or solid group, based on the presence of a GGO component. Results: Of the cases, 215 (34%) were classed as c‐stage IA1 (T1mi: 88, T1a‐GGO: 102, T1a‐solid: 25), 255 (40%) as c‐stage IA2 (T1b‐GGO: 122, T1b‐solid: 133), and 164 (26%) as c‐stage IA3 (T1c‐GGO: 44, T1c‐solid: 120). Among the 546 c‐stage IA cases excluding the T1mi lesions, Cox regression analysis revealed that presence of GGO was an independently significant prognosticator (p = 0.024). The result was validated in 494 c‐stage IA lung adenocarcinomas with a nonpredominant GGO component, showing the presence of GGO as a significant prognosticator (p = 0.048). When we evaluated the prognostic impact of GGO presence in each clinical stage, the 5‐year overall survival (OS) was significantly different between the GGO and solid groups (IA1: 97.8% versus 86.6%, p = 0.026; IA2: 89.3% versus 75.2%, p = 0.007; IA3: 88.5% versus 62.3%, p = 0.003). Furthermore, the 5‐year overall survival b was distinct in parallel similar pathologic findings when comparing a lepidic versus an invasive component (IA1: 97.9% versus 85.6%, p = 0.031; IA2: 86.1% versus 69.4%, p = 0.007; IA3: 77.5% versus 55.8%, p < 0.001). Conclusions: Clinicopathologic and oncologic outcomes were disparate based on the presence of a GGO component in the eighth edition TNM classification of c‐stage IA lung adenocarcinoma.

中文翻译：

---

临床分期 IA 肺腺癌中基于磨玻璃混浊成分的不同临床病理特征和预后

介绍：我们根据小尺寸肺腺癌中磨玻璃样混浊（GGO）成分的存在评估了临床病理特征和预后的差异。方法：我们回顾性研究了在第八版 TNM 分类中归类为 c 期 IA 的 634 例肺腺癌。分期是根据通过薄层计算机断层扫描测量的固体成分大小来定义的。根据 GGO 成分的存在，所有肿瘤被分为 GGO 或实体组。结果：在这些病例中，215 例（34%）被归类为 c 期 IA1（T1mi：88，T1a-GGO：102，T1a-solid：25），255 例（40%）被归类为 c 期 IA2（T1b-GGO） : 122, T1b-solid: 133), 164 (26%) 作为 c-stage IA3 (T1c-GGO: 44, T1c-solid: 120)。在不包括 T1mi 病变的 546 例 c 期 IA 病例中，Cox 回归分析显示 GGO 的存在是一个独立的显着预后因素（p = 0.024）。结果在 494 例具有非主要 GGO 成分的 c 期 IA 肺腺癌中得到验证，表明 GGO 的存在是一个重要的预后因素（p = 0.048）。当我们评估 GGO 在每个临床阶段的预后影响时，GGO 组和实体组的 5 年总生存率 (OS) 显着不同（IA1：97.8% 对 86.6%，p = 0.026；IA2：89.3% 对75.2%，p = 0.007；IA3：88.5% 对 62.3%，p = 0.003）。此外，当比较贴壁和侵入性成分时，5 年总生存率 b 在平行相似的病理结果中是不同的（IA1：97.9% 对 85.6%，p = 0.031；IA2：86.1% 对 69.4%，p = 0.007；IA3 ：77.5% 与 55.8%，p < 0.001）。结论：